Metraipolis › archive › dc_38ab8fd02549
The novel ALK K1150dup mutation mediates resistance to frontline lorlatinib and retains sensitivity to gilteritinib — Europe PMC PMID:42129432
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42129432
- DOI
- 10.1038/s41698-[numero omesso]-z
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-08T02:08:59.639Z
- SHA-256 of the archived text
7caf86623fbb9a29aefd87233ca75741fd4e260e7cb697e93e0a26e2e919146a- Stable URL of this page
https://metraipolis.com/documento/dc_38ab8fd02549
How to cite
The novel ALK K1150dup mutation mediates resistance to frontline lorlatinib and retains sensitivity to gilteritinib — Europe PMC PMID:42129432 — Europe PMC (en), https://europepmc.org/article/MED/42129432 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_38ab8fd02549 (Metraipolis archive dc_38ab8fd02549, sha256 7caf86623fbb9a29aefd87233ca75741fd4e260e7cb697e93e0a26e2e919146a)
BibTeX
@misc{dc38ab8fd02549,
title = {The novel ALK K1150dup mutation mediates resistance to frontline lorlatinib and retains sensitivity to gilteritinib — Europe PMC PMID:42129432},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42129432},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_38ab8fd02549; sha256 7caf86623fbb9a29aefd87233ca75741fd4e260e7cb697e93e0a26e2e919146a},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42129432. Agents can read the archived copy with the MCP tool read_document.